ReviewThe Lancet. Oncology2025
Advances and challenges in precision imaging.
Review in The Lancet. Oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed.
- Review Article: Biomarkers in Liver Transplantation for Hepatocellular Carcinoma: Towards Precision Medicine.Alimentary pharmacology & therapeutics · 2026Review
- Specific PET Imaging for Precision Management of Lung Cancer: Advances, Clinical Translation and Future Directions.Chemical & biomedical imaging · 2026Review
- Targeting Fibroblast Activation Protein with [177Lu]Lu-FAP-2286 in Patients with Advanced Solid Tumors in the Phase I LuMIERE Trial.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026Article
- High mannose content of mesenchymal glioblastoma correlates with hydroxyl proton transfer-weighted (HPTw) MRI as noninvasive biomarker of tumor aggressiveness.Science advances · 2026Article
- Nanozyme-Driven Signal Amplification in Cancer Biosensing: Innovations Toward Precision and Point-of-Care Oncology.Micromachines · 2026Review
- Article
- Detection of Aggressive Mesenchymal Glioblastoma by Mannose-Weighted CEST MRI.bioRxiv : the preprint server for biology · 2026Article
- STING-Activating nanoplatforms for image-guided sonodynamic cancer therapy.Molecular cancer · 2026Article
- Driving clinical excellence through a management driven framework for integrating nuclear medicine into hospital ecosystems.Frontiers in nuclear medicine · 2026Article
- An efficient method for site-selective boronation of peptides and proteins applied in magnified bacterial imaging.Nature communications · 2025Article
- Harnessing Photo-Energy Conversion in Nanomaterials for Precision Theranostics.Advanced materials (Deerfield Beach, Fla.) · 2025Review
- Review
- Targeting cancer-associated fibroblasts for real-time intraoperative tumor identification with a spray-on fluorescent probe.Science advances · 2025Article
- Far-Red Spray-On Imaging Probes for FAP-Targeted Cancer Surgery.Bioconjugate chemistry · 2025Article
- Theranostics in nuclear medicine: the era of precision oncology.Medical oncology (Northwood, London, England) · 2025Review
- Molecular imaging using (nano)probes: cutting-edge developments and clinical challenges in diagnostics.RSC advances · 2025Review
- Foundation model embeddings for quantitative tumor imaging biomarkers.Research square · 2025Article
- Article
- Large Language Models in Cancer Imaging: Applications and Future Perspectives.Journal of clinical medicine · 2025Review
- Increases in the Association Between the Rates of Synchronous and Metachronous Metastases over Time.Journal of clinical medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Technological innovations in genomics and related fields have facilitated large sequencing efforts, supported new biological discoveries in cancer, and spawned an era of liquid biopsy biomarkers. Despite these advances, precision oncology has practical constraints, partly related to cancer's biological diversity and spatial and temporal complexity. Advanced imaging technologies are being developed to address some of the current limitations in early detection, treatment selection and planning, drug delivery, and therapeutic response, as well as difficulties posed by drug resistance, drug toxicity, disease monitoring, and metastatic evolution. We discuss key areas of advanced imaging for improving cancer outcomes and survival. Finally, we discuss practical challenges to the broader adoption of precision imaging in the clinic and the need for a robust translational infrastructure.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.